title: [Mechanisms of resistance to target therapy].
abstract: Cancer therapies are changing from general chemotherapeutic agents to drugs that target specific proteins and signaling pathways. Target therapies, which attack specific cancer cells without harming normal cells, have the potential to treat cancers with fewer side effects than conventional therapies. This article reviews mechanisms of resistance to targeted agents, including genetic resistance, bypass track resistance, and defect growth arrest/apoptosis. Secondary mutations reduce the biologic effects of inhibiting the driver oncoprotein. Interaction and cross signaling from targeting receptor to other growth factor receptors may potentially contribute to therapeutic resistance. They explain why solid tumors develop resistance to target therapies in a highly reproducible fashion.
authors.affiliation: Department of Gastroenterology, Gastroenterology Center, The Cancer Institute Hospital.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Matsusaka
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000235:genetics / Q000276:immunology*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D015398:Signal Transduction
chemical_list: D000970:Antineoplastic Agents; D066246:ErbB Receptors